Summary
The incidence of myopia is predicted to rise from 28% of the global population in 2010 to almost 50% in 2050. Factors such as population aging and increase of hours spent in front of screens are driving the increase in global eye deficits. Vision impairments reduce the quality of life, affect economic and educational opportunities and increase the risk of death. This is particularly important for vulnerable groups such as elderly, children, workers and drivers. Overall, WHO reported that uncorrected vision was responsible for €241bn of productivity loss per year worldwide.
Our innovative Virtual Eye Model System (VEMoS) is based on patented revolutionary ophthalmic diagnostic devices (CSO’s MS-39 tomographer/topographer and the unique open-field aberrometer), as well as on innovative simulation software developed by Vissum. Overall, our innovation provides personalised clinical-decision support based on each patient’s eye measurements and neural network simulations of post-surgery outcomes, improving surgery success and patient satisfaction rates.
By combining CSO’s ophthalmic high-tech hardware design, manufacturing and commercialisation skills with Vissum’s refractive surgery and software development and independent clinical testing by CHUC and AUH, this project is expected to bring economic, social and health impacts, including progress towards achieving the EC action plan on personalised medicine “ICPerMed”. Our goal is to mature, scale-up and demonstrate the production of the VEMoS system, targeting ophthalmology clinics as clients, and with the aim to standardise refractive surgery decision making and revolutionise the refractive surgery field with personalised treatments.
A successful VEMoS project will allow us to create measurable impacts on our companies, quantified as accumulated revenue of €145.3m in five years (2022-2026), equal to accumulated operating profit of €58.2m, creating 60 full time employments, and generating €37m in reduced customer costs.
Our innovative Virtual Eye Model System (VEMoS) is based on patented revolutionary ophthalmic diagnostic devices (CSO’s MS-39 tomographer/topographer and the unique open-field aberrometer), as well as on innovative simulation software developed by Vissum. Overall, our innovation provides personalised clinical-decision support based on each patient’s eye measurements and neural network simulations of post-surgery outcomes, improving surgery success and patient satisfaction rates.
By combining CSO’s ophthalmic high-tech hardware design, manufacturing and commercialisation skills with Vissum’s refractive surgery and software development and independent clinical testing by CHUC and AUH, this project is expected to bring economic, social and health impacts, including progress towards achieving the EC action plan on personalised medicine “ICPerMed”. Our goal is to mature, scale-up and demonstrate the production of the VEMoS system, targeting ophthalmology clinics as clients, and with the aim to standardise refractive surgery decision making and revolutionise the refractive surgery field with personalised treatments.
A successful VEMoS project will allow us to create measurable impacts on our companies, quantified as accumulated revenue of €145.3m in five years (2022-2026), equal to accumulated operating profit of €58.2m, creating 60 full time employments, and generating €37m in reduced customer costs.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/878748 |
| Start date: | 01-12-2019 |
| End date: | 30-09-2023 |
| Total budget - Public funding: | 3 935 335,00 Euro - 2 997 269,00 Euro |
Cordis data
Original description
The incidence of myopia is predicted to rise from 28% of the global population in 2010 to almost 50% in 2050. Factors such as population aging and increase of hours spent in front of screens are driving the increase in global eye deficits. Vision impairments reduce the quality of life, affect economic and educational opportunities and increase the risk of death. This is particularly important for vulnerable groups such as elderly, children, workers and drivers. Overall, WHO reported that uncorrected vision was responsible for €241bn of productivity loss per year worldwide.Our innovative Virtual Eye Model System (VEMoS) is based on patented revolutionary ophthalmic diagnostic devices (CSO’s MS-39 tomographer/topographer and the unique open-field aberrometer), as well as on innovative simulation software developed by Vissum. Overall, our innovation provides personalised clinical-decision support based on each patient’s eye measurements and neural network simulations of post-surgery outcomes, improving surgery success and patient satisfaction rates.
By combining CSO’s ophthalmic high-tech hardware design, manufacturing and commercialisation skills with Vissum’s refractive surgery and software development and independent clinical testing by CHUC and AUH, this project is expected to bring economic, social and health impacts, including progress towards achieving the EC action plan on personalised medicine “ICPerMed”. Our goal is to mature, scale-up and demonstrate the production of the VEMoS system, targeting ophthalmology clinics as clients, and with the aim to standardise refractive surgery decision making and revolutionise the refractive surgery field with personalised treatments.
A successful VEMoS project will allow us to create measurable impacts on our companies, quantified as accumulated revenue of €145.3m in five years (2022-2026), equal to accumulated operating profit of €58.2m, creating 60 full time employments, and generating €37m in reduced customer costs.
Status
SIGNEDCall topic
EIC-FTI-2018-2020Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
